(1) High levels of human eNOS and nNOS can be produced using the Sf 21/baculovirus expression system. (2) Recombinant iNOS, although produced at lower levels, provides significant amounts of enzyme that can be purified for further biochemical characterization. (3) Recombinant baculovirus-derived human NO synthase isozymes have biochemical properties that are highly similar to their native counterparts. (4) Large-scale production of recombinant NO synthase enzymes reduces the risk of batch-to-batch variation. (5) The production of recombinant human NO synthases obviates the need for a supply of tissue and also reduces the risks associated with handling human material.
